Hyponatremia linked to metabolic bone disease in epilepsy

By

By Reuters Staff

NEW YORK (Reuters Health) - In patients with epilepsy, hyponatremia - a common side effect of several antiepileptic drugs (AEDs) - is independently associated with decreased bone-mineral density (BMD) and an increased risk of osteoporosis, researchers from Denmark report.

As many as 46% of patients with epilepsy experience hyponatremia, according to Dr. Sarah Seberg Diemar of Rigshospitalet Glostrup and Odense University Hospital and colleagues.

Dr. Diemar's team used data from 695 patients attending the tertiary outpatient epilepsy clinic to investigate whether the occurrence of osteoporosis is associated with hyponatremia in these patients.

Among these patients, 10.4% had hyponatremia (plasma sodium of 135 mmol/L or lower). Patients with hyponatremia weighed less, were older at the time of the dual energy X-ray scan, more frequently used at least two AEDs and were more often treated with enzyme-inducing AEDs, compared with the non-hyponatremic group.

Patients with hyponatremia had significantly lower BMD T-scores in the lumbar spine, femoral neck and total femur, compared with patients without hyponatremia, the researchers report in Bone, online March 21.

Significantly more patients with hyponatremia (25.0%) than without (10.3%) had osteoporosis, and patients with hyponatremia had 2.91-fold increased odds of having osteoporosis at any site (P=0.001).

The odds of having osteoporosis were increased 4.81-fold among patients treated with an enzyme-inducing AED (P<0.001).

"A finding of hyponatremia in patients with epilepsy should therefore warrant further examination of the patient's bone health to exclude or treat existing osteoporosis," the researchers conclude. "Further studies are needed to increase our knowledge on this association as well as prospective studies looking into the underlying mechanisms behind hyponatremia-induced osteoporosis in patients with epilepsy."

Eisai Co., Ltd. provided an unrestricted research grant that was used to fund the study. Two of the six authors have received research grants from the company.

Dr. Diemar did not respond to a request for comments.

SOURCE: https://bit.ly/2Ve1UOU

Bone 2019.

Related Articles

IBD patients who switch from infliximab to biosimilar see mixed results

By Will Boggs MD NEW YORK (Reuters Health) - Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical Read More »

Yale study revives cellular activity in pig brains hours after death

By Steve Gorman (Reuters) - Yale University scientists have succeeded in restoring basic cellular activity in pigs' brains hours after their deaths in a finding that may one day lead to advances in Read More »

Penalizing US hospitals for readmissions doesn't benefit heart failure patients

By Marilynn Larkin NEW YORK (Reuters Health) - Implementation of the U.S. Hospital Readmissions Reduction Program (HRRP) in the past decade has not been associated with changes in hospital length of Read More »